Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. Ca-Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887. doi:10.1016/j.cell.2011.08.03921925313
   PubMed Web of Science ®Google Scholar
• Martino EC, Misso G, Pastina P, et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016;2:16025. doi:10.1038/cddiscovery.2016.927752361
   PubMed Web of Science ®Google Scholar
• Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190–3200. doi:10.1172/JCI7021223908119
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009;20(4):158–163. doi:10.1684/ecn.2009.017020167554
   PubMed Web of Science ®Google Scholar
• Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol-Mech. 2007;2:251–275. doi:10.1146/annurev.pathol.2.010506.134925
   PubMed Web of Science ®Google Scholar
• Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:15. doi:10.1200/jco.2015.33.15_suppl.8009
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa150764326412456
   PubMed Web of Science ®Google Scholar
• Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–3933. doi:10.1200/JCO.2017.74.306229023213
   PubMed Web of Science ®Google Scholar
• Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized Phase III clinical trial. J Thorac Oncol. 2019;14:867–875. doi:10.1016/j.jtho.2019.01.00630659987
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-726712084
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa180100529658856
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa181086530280635
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X27979383
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa171694829863955
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa180969730280658
   PubMed Web of Science ®Google Scholar
• Rodriguez-Molinero A, Lopez-Dieguez M, Banegas JR. Tissue homeostasis and cancer. Med Hypotheses. 2007;68(6):1333–1341. doi:10.1016/j.mehy.2006.10.03317157444
   PubMed Web of Science ®Google Scholar
• Brahmer J, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): clinical characteristics of long-term survivors. Cancer Res. 2017;77. doi:10.1158/1538-7445.Am2017-Ct077
   Web of Science ®Google Scholar
• Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res. 2015;4(6):721–727. doi:10.3978/j.issn.2218-6751.2015.10.1126798581
   PubMedGoogle Scholar
• Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17(8):E347–E362. doi:10.1016/S1470-2045(16)30123-127511159
   PubMed Web of Science ®Google Scholar
• Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23(2–3):263–272. doi:10.1385/IR:23:2-3:26311444391
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257. doi:10.1038/3502522011001068
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727–739. doi:10.1038/nrc90512360276
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (vol 10, pg 145, 2004). Nat Med. 2004;10(6):649. doi:10.1038/nm0604-649c
   Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi:10.1056/NEJMoa06188417167137
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Young T, Fages S, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study results of an exploratory analysis. J Thorac Oncol. 2012;7(11):1707–1712. doi:10.1097/JTO.0b013e318265b50023059774
   PubMed Web of Science ®Google Scholar
• Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized Phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with Stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349–U4377. doi:10.1200/JCO.2012.47.962624145346
   PubMed Web of Science ®Google Scholar
• Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044–1052. doi:10.1093/annonc/mdu09824585722
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, Phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204. doi:10.1200/JCO.2014.59.442426014294
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673. doi:10.1016/S0140-6736(14)60845-X24933332
   PubMed Web of Science ®Google Scholar
• Gottfried M, Bennouna J, Bondarenko I, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 study. Target Oncol. 2017;12(4):475–485. doi:10.1007/s11523-017-0517-228702806
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. doi:10.1016/S1470-2045(13)70586-224411639
   PubMed Web of Science ®Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73. doi:10.1016/j.lungcan.2016.10.01127987591
   PubMed Web of Science ®Google Scholar
• Sun YK, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9. doi:10.1186/s13045-016-0332-8
   Web of Science ®Google Scholar
• Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.02629454091
   PubMed Web of Science ®Google Scholar
• Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer. 2018;28(1):152–160. doi:10.1097/IGC.000000000000112928953502
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.303930098152
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175. doi:10.1200/JCO.2009.26.760920516446
   PubMed Web of Science ®Google Scholar
• Wang CY, Thudium KB, Han MH, et al. In vitro characterization of the Anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-004024872026
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa120069022658127
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-730955977
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019. doi:10.1016/S1470-2045(19)30167-6
   Web of Science ®Google Scholar
• Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(18):2. doi:10.1200/JCO.2018.36.18_suppl.LBA9000
   Web of Science ®Google Scholar
• Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00621
   PubMed Web of Science ®Google Scholar
• de Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457–474. doi:10.1038/nrc.2017.5128706266
   PubMed Web of Science ®Google Scholar
• Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515–523. doi:10.3978/j.issn.2218-6751.2015.06.0926629420
   PubMed Web of Science ®Google Scholar
• Bouzin C, Brouet A, De Vriese J, DeWever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178(3):1505–1511. doi:10.4049/jimmunol.178.3.150517237399
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses Type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674–6682. doi:10.1158/1078-0432.CCR-07-521218927310
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–4166.9834220
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (vol 2, pg 1096, 1996). Nat Med. 1996;2(11):1267. doi:10.1038/nm1096-1096
   Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615. doi:10.1038/nm.354124793239
   PubMed Web of Science ®Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878–4886. doi:10.1182/blood-2002-07-195612586633
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. 2017;95(4):325–332. doi:10.1038/icb.2016.12627999432
   PubMed Web of Science ®Google Scholar
• Garber K. Promising early results for immunotherapy-antiangiogenesis combination. J Natl Cancer Inst. 2014;106:11. doi:10.1093/jnci/dju061
   Google Scholar
• Manegold C, Dingemans AMC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12(2):194–207. doi:10.1016/j.jtho.2016.10.00327729297
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539–549. doi:10.1158/0008-5472.CAN-12-232523108136
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–3736. doi:10.1158/0008-5472.CAN-04-007415172975
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2–3):72–84. doi:10.1016/j.mvr.2007.05.00317560615
   PubMed Web of Science ®Google Scholar
• Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. Oncotargets Ther. 2018;11:6901–6909. doi:10.2147/OTT.S172042
   PubMed Web of Science ®Google Scholar
• Liang J, Cheng Q, Huang J, et al. Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI. Angiogenesis. 2019;22:457–470. doi:10.1007/s10456-019-09670-431147887
   PubMed Web of Science ®Google Scholar
• Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2012;130(8):1948–1959. doi:10.1002/ijc.2621921633954
   PubMed Web of Science ®Google Scholar
• Farsaci B, Donahue RN, Coplin MA, et al. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res. 2014;2(11):1090–1102. doi:10.1158/2326-6066.CIR-14-007625092771
   PubMed Web of Science ®Google Scholar
• Huang YH, Yuan JP, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. P Natl Acad Sci USA. 2012;109(43):17561–17566. doi:10.1073/pnas.1215397109
   PubMed Web of Science ®Google Scholar
• Bonanno L, De Paoli A, Zulato E, et al. LKB1 expression correlates with increased survival in patients with advanced non-small cell lung cancer treated with chemotherapy and bevacizumab. Clin Cancer Res. 2017;23(13):3316–3324. doi:10.1158/1078-0432.CCR-16-241028119362
   PubMed Web of Science ®Google Scholar
• Curtarello M, Zulato E, Nardo G, et al. VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells. Cancer Res. 2015;75(1):120–133. doi:10.1158/0008-5472.CAN-13-203725381153
   PubMed Web of Science ®Google Scholar
• Nardo G, Favaro E, Curtarello M, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011;71(12):4214–4225. doi:10.1158/0008-5472.CAN-11-024221546569
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy (vol 41, pg 49, 2014). Immunity. 2014;41(5):866. doi:10.1016/j.immuni.2014.09.021
   Web of Science ®Google Scholar
• Zulato E, Curtarello M, Nardo G, Indraccolo S. Metabolic effects of anti-angiogenic therapy in tumors. Biochimie. 2012;94(4):925–931. doi:10.1016/j.biochi.2012.01.00122245704
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12. doi:10.1186/s12967-014-0294-y
   PubMed Web of Science ®Google Scholar
• Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy. Clin Cancer Res. 2006;12(22):6808–6816. doi:10.1158/1078-0432.CCR-06-155817121902
   PubMed Web of Science ®Google Scholar
• Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One. 2013;8(6):e65757. doi:10.1371/journal.pone.006575723799045
   PubMed Web of Science ®Google Scholar
• Tao LL, Huang GC, Shi SJ, Chen LB. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol. 2014;31:1. doi:10.1007/s12032-014-0374-0
   Web of Science ®Google Scholar
• Zhao S, Jiang T, Li X, Zhou C. Combining anti-angiogenesis and immunotherapy enhances antitumor effect in lung cancer. Ann Oncol. 2016;27:S288–S288.
   Web of Science ®Google Scholar
• Herbst RS, Bendell JC, Isambert N, et al. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. J Clin Oncol. 2016;34:15. doi:10.1200/JCO.2016.34.15_suppl.3056
   Web of Science ®Google Scholar
• Rizvi NA, Antonia SJ, Shepherd FA, et al. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Int J Radiat Oncol. 2014;90:S32–S32. doi:10.1016/j.ijrobp.2014.08.206
   Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-030922878
   PubMed Web of Science ®Google Scholar
• Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms Phase Ib study. Ann Oncol. 2016;27(12):2242–2250. doi:10.1093/annonc/mdw41627765756
   PubMed Web of Science ®Google Scholar